The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx ... before it gets to the brain,” Vertex’s Dr. David Altshuler, told The Associated ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for ... before it gets to the brain,” Vertex’s Dr. David Altshuler, told the Associated Press last ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Dr. Scott Ryan, MD works in Boston, MA as an Orthopedic Specialist and has 20 years experience. Dr. Ryan is board certified in Orthopedic Surgery and graduated from Tufts University in 2005.

Officials across Greater Boston say they’re trying to overcome ... In her interview with the radio station, Wu also called out Dr. Phil for following along with border czar Tom Homan and federal ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...